NCT05997160

Brief Summary

The goal of this observational study is to explore a standardized sample process for improving the accuracy of vaginal microbiota evaluation and to explore a more complete and comprehensive method for vaginal microbiota evaluation based on gram staining.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
5,590

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2023

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 10, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 18, 2023

Completed
14 days until next milestone

Study Start

First participant enrolled

September 1, 2023

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

August 18, 2023

Status Verified

August 1, 2023

Enrollment Period

1.8 years

First QC Date

August 10, 2023

Last Update Submit

August 10, 2023

Conditions

Outcome Measures

Primary Outcomes (4)

  • The score for smear

    This score consists of uniformity, impurities, cell degeneration, and clarity for evaluating a smear.

    December 2023

  • Diagnosis of vaginitis type

    The Diagnosis of vaginitis type based on Gram-stained smear and antigen testing, including aerobic vaginitis(AV), bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), trichomonal vaginitis (TV), and normal.

    March 2024

  • Relative Abundance

    Relative Abundance is from 16S rRNA gene sequencing and metagenomic sequencing for patients without clearly diagnosis.

    May 2024

  • Intensity

    The intensity is tested by liquid chromatography-tandem mass spectrometry for targeted metabolites for patients without clearly diagnosis.

    May 2024

Study Arms (1)

hospital name + infection type + number

There is no intervention.

Eligibility Criteria

Age15 Years - 49 Years
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

VENUS study plans to enrol 5590 participants, aged 15-49 years, from visiting our research settings across the country who evaluate vaginal discharge based on Gram-stained smear.

You may qualify if:

  • Non-pregnant women who visit our research settings and conduct vaginal discharge examination based on Gram-stained smear.
  • No sexual intercourse, vaginal douching, or vaginal medication within the last 72 hours.
  • Not during menstruation (menstrual period ended ≥3 days ago).

You may not qualify if:

  • Receiving systemic or vaginal antifungal or antibiotic treatment within the past week.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Vaginitis

Condition Hierarchy (Ancestors)

Vaginal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Fengxia Xue, PhD

    Tianjin Medical University General Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Fengxia Xue, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of the Medical Center for Obstetrics and Gynecology

Study Record Dates

First Submitted

August 10, 2023

First Posted

August 18, 2023

Study Start

September 1, 2023

Primary Completion

June 30, 2025

Study Completion

June 30, 2025

Last Updated

August 18, 2023

Record last verified: 2023-08